Abbisko, AstraZeneca Team Up on Lung Cancer Drug Combo After China Trial Clearance

Abbisko Therapeutics Co. Ltd. on Wednesday entered into a strategic collaboration with AstraZeneca Plc (NYSE: AZN ) to jointly develop a novel combination therapy for patients with EGFR-mutated and PD-L1 positive non-small cell lung cancer (NSCLC). The partnership follows regulatory clearance in China for a Phase 1/2 study evaluating Abbisko’s oral PD-L1 inhibitor, lumipodlin (ABSK043), alongside AstraZeneca’s EGFR-targeted therapy, TAGRISSO (osimertinib). Read Also: AstraZeneca Advances Rare Bone Disease Pipeline While Enhertu Expands In Europe China Clears Phase 1/2 Combination Study The National Medical Products Administration (NMPA) cleared the investigational new drug (IND) application for the study on May 20, 2026. The multicenter, open-label Phase 1/2 trial will assess the safety and efficacy of combining lumipodlin with Tagrisso in patients with locally advanced or...